{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T16:48:11Z","timestamp":1748623691957},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"DOI":"10.7759\/cureus.65971","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T23:41:46Z","timestamp":1722555706000},"source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the Efficacy of Infliximab in Inflammatory Bowel Disease: A Systematic Review of the Literature"],"prefix":"10.7759","author":[{"given":"Maria P","family":"Vallejo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo  P","family":"Jaramillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Luis","family":"Guan\u00edn Cabrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria G","family":"Cueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Navarro Grijalva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Grandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2020.00029","article-title":"Correlation of serum levels of anti-tumor necrosis factor agents with perianal fistula healing in Crohn's disease: a narrative review","volume":"19","author":"Miranda EF","year":"2021","unstructured":"Miranda EF, Nones RB, Kotze PG. Correlation of serum levels of anti-tumor necrosis factor agents with perianal fistula healing in Crohn's disease: a narrative review. Intest Res. 2021, 19:255-64. 10.5217\/ir.2020.00029","journal-title":"Intest Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0352-2","article-title":"Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?","volume":"17","author":"Argollo M","year":"2020","unstructured":"Argollo M, Kotze PG, Kakkadasam P, D'Haens G. Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?. Nat Rev Gastroenterol Hepatol. 2020, 17:702-10. 10.1038\/s41575-020-0352-2","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32196-2","article-title":"Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn\u2019s disease: an international, randomised, double-blind, phase 3 non-inferiority study","volume":"27","author":"Ye BD","year":"2019","unstructured":"Ye BD, Pesegova M, Alexeeva O, et al.. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn\u2019s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet Lond Engl. 2019, 27:1699-707. 10.1016\/S0140-6736(18)32196-2","journal-title":"Lancet Lond Engl"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30082-7","article-title":"Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial","volume":"3","author":"Strik AS","year":"2018","unstructured":"Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, et al.. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. Lancet Gastroenterol Hepatol. 2018, 3:404-12. 10.1016\/S2468-1253(18)30082-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izx086","article-title":"Full interchangeability in regard to immunogenicity between the infliximab reference biologic and biosimilars \r\n CT-P13 and SB2 in inflammatory bowel disease","volume":"24","author":"Fiorino G","year":"2018","unstructured":"Fiorino G, Ruiz-Arg\u00fcello MB, Maguregui A, et al.. Full interchangeability in regard to immunogenicity between the infliximab reference biologic and biosimilars \r\n CT-P13 and SB2 in inflammatory bowel disease. Inflamm Bowel Dis. 2018, 24:601-6. 10.1093\/ibd\/izx086","journal-title":"Inflamm Bowel Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw203","article-title":"Prediction of short- and medium-term efficacy of biosimilar infliximab therapy. do trough levels and antidrug antibody levels or clinical and biochemical markers play the more important role?","volume":"11","author":"Gonczi L","year":"2017","unstructured":"Gonczi L, Vegh Z, Golovics PA, et al.. Prediction of short- and medium-term efficacy of biosimilar infliximab therapy. do trough levels and antidrug antibody levels or clinical and biochemical markers play the more important role?. J Crohns Colitis. 2017, 11:697-705. 10.1093\/ecco-jcc\/jjw203","journal-title":"J Crohns Colitis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American gastroenterological association institute clinical guidelines committee. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein JD","year":"2017","unstructured":"Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S. American gastroenterological association institute clinical guidelines committee. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017, 153:827-34. 10.1053\/j.gastro.2017.07.032","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw085","article-title":"Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis","volume":"10","author":"Farkas K","year":"2016","unstructured":"Farkas K, Rutka M, Golovics PA, et al.. Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. J Crohns Colitis. 2016, 10:1273-8. 10.1093\/ecco-jcc\/jjw085","journal-title":"J Crohns Colitis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309290","article-title":"Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima","volume":"65","author":"Ben-Horin S","year":"2016","unstructured":"Ben-Horin S, Yavzori M, Benhar I, et al.. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut. 2016, 65:1132-8. 10.1136\/gutjnl-2015-309290","journal-title":"Gut"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e3182a77b41","article-title":"Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study","volume":"19","author":"Paul S","year":"2013","unstructured":"Paul S, Del Tedesco E, Marotte H, et al.. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2013, 19:2568-76. 10.1097\/MIB.0b013e3182a77b41","journal-title":"Inflamm Bowel Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands BE","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, et al.. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004, 350:876-85. 10.1056\/NEJMoa030815","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"4","author":"Hanauer SB","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al.. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet Lond Engl. 2002, 4:1541-9. 10.1016\/S0140-6736(02)08512-4","journal-title":"Lancet Lond Engl"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5009\/gnl220005","article-title":"Early infliximab trough levels predict the long-term efficacy of infliximab in a randomized controlled trial in patients with active crohn\u2019s disease comparing, between ct-p13 and originator infliximab","volume":"17","author":"Park J","year":"2023","unstructured":"Park J, Cheon JH, Lee KM, et al.. Early infliximab trough levels predict the long-term efficacy of infliximab in a randomized controlled trial in patients with active crohn\u2019s disease comparing, between ct-p13 and originator infliximab. Gut Liver. 2023, 17:430-40. 10.5009\/gnl220005","journal-title":"Gut Liver"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00385-5","article-title":"Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial","volume":"8","author":"Louis E","year":"2023","unstructured":"Louis E, Resche-Rigon M, Laharie D, et al.. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol. 2023, 8:215-27. 10.1016\/S2468-1253(22)00385-5","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref15","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71.","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0254-6450.2017.10.028","article-title":"Bias risk assessment: (3) Revised Cochrane bias risk assessment tool for individual randomized, cross-over trials (RoB2.0) (Article in Chinese)","volume":"38","author":"Wu SS","year":"2017","unstructured":"Wu SS, Sun F, Zhan SY. Bias risk assessment: (3) Revised Cochrane bias risk assessment tool for individual randomized, cross-over trials (RoB2.0) (Article in Chinese). Zhonghua Liu Xing Bing Xue Za Zhi. 2017, 38:1436-40. 10.3760\/cma.j.issn.0254-6450.2017.10.028","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.4314","article-title":"VE303, a defined bacterial consortium, for prevention of recurrent Clostridioides difficile infection: A randomized clinical trial","volume":"329","author":"Louie T","year":"2023","unstructured":"Louie T, Golan Y, Khanna S, et al.. VE303, a defined bacterial consortium, for prevention of recurrent Clostridioides difficile infection: A randomized clinical trial. JAMA. 2023, 329:1356-66. 10.1001\/jama.2023.4314","journal-title":"JAMA"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.21316","article-title":"Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial","volume":"326","author":"Syversen SW","year":"2021","unstructured":"Syversen SW, J\u00f8rgensen KK, Goll GL, et al.. Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial. JAMA. 2021, 326:2375-84. 10.1001\/jama.2021.21316","journal-title":"JAMA"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.4172","article-title":"Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a randomized clinical trial","volume":"325","author":"Syversen SW","year":"2021","unstructured":"Syversen SW, Goll GL, J\u00f8rgensen KK, et al.. Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a randomized clinical trial. JAMA. 2021, 325:1744-54. 10.1001\/jama.2021.4172","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber S","year":"2021","unstructured":"Schreiber S, Ben-Horin S, Leszczyszyn J, et al.. Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. Gastroenterology. 2021, 160:2340-53. 10.1053\/j.gastro.2021.02.068","journal-title":"Gastroenterology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-020-00438-7","article-title":"Efficacy and safety of CT-P13 in inflammatory bowel disease after switching from originator infliximab: exploratory analyses from the NOR-SWITCH main and extension trials","volume":"34","author":"J\u00f8rgensen KK","year":"2020","unstructured":"J\u00f8rgensen KK, Goll GL, Sexton J, et al.. Efficacy and safety of CT-P13 in inflammatory bowel disease after switching from originator infliximab: exploratory analyses from the NOR-SWITCH main and extension trials. BioDrugs. 2020, 34:681-94. 10.1007\/s40259-020-00438-7","journal-title":"BioDrugs"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.01.004","article-title":"Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal crohn\u2019s disease","volume":"154","author":"D'Haens G","year":"2018","unstructured":"D'Haens G, Vermeire S, Lambrecht G, et al.. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal crohn\u2019s disease. Gastroenterology. 2018, 154:1343-1351.e1. 10.1053\/j.gastro.2018.01.004","journal-title":"Gastroenterology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307883","article-title":"The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease","volume":"64","author":"Vande Casteele N","year":"2015","unstructured":"Vande Casteele N, Khanna R, Levesque BG, et al.. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut. 2015, 64:1539-45. 10.1136\/gutjnl-2014-307883","journal-title":"Gut"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005887","article-title":"Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial","volume":"4","author":"Buhl SS","year":"2014","unstructured":"Buhl SS, Steenholdt C, Brynskov J, Thomsen O\u00d8, Bendtzen K, Ainsworth MA. Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial. BMJ Open. 2014, 4:e005887. 10.1136\/bmjopen-2014-005887","journal-title":"BMJ Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/272200-evaluating-the-efficacy-of-infliximab-in-inflammatory-bowel-disease-a-systematic-review-of-the-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T23:41:53Z","timestamp":1722555713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/272200-evaluating-the-efficacy-of-infliximab-in-inflammatory-bowel-disease-a-systematic-review-of-the-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.65971","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}